According to the Financial Times, MSD – known as Merck & Co in the US and Canada – is in the final stages of a $10 billion ...

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

Whether stemming from early childhood adversity, combat exposure, or interpersonal abuse, trauma leaves long-term imprints on ...

Improving efficiencies and uncomplicating processes are critical to the future success of NHS Trusts across the country. The ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...

Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...

A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young ...

The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

Medistry LLC is the internet registry operator of the .med top level domain (TLD). Currently in a period of pre-registration ...

South Korean electronics giant Samsung has continued a push into the health category with an agreement to buy Xealth, a ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...